ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 2584

Spatially Resolved Transcriptomics Reveal Macrophage Heterogeneity in Giant Cell Arteritis
Abstract Number: 2585

The effect of prophylactic colchicine use on gene expression in gout
Abstract Number: 2586

Estimated Carrier Prevalence of HLA-B*58:01 Across Diverse Populations in the US and Globally
Abstract Number: 2587

Nanoencapsulated Sirolimus Plus Pegadricase Reduced Disease Burden in Patients With Uncontrolled Gout: Results From the Phase 3 DISSOLVE Trials
Abstract Number: 2588

Nanoencapsulated Sirolimus plus Pegadricase (NASP) Demonstrates a Reduction in Gout Flares: Results from the Phase 3 DISSOLVE Studies
Abstract Number: 2589

Multi-omics Integration Reveals Gut Microbiota–Metabolite Dysregulation in Gout with Metabolic Syndrome
Abstract Number: 2590

Translating findings on urate-metabolizing bacterial genes and urate levels at the human population level: a gut microbiome analysis of three independent cohorts of men and women
Abstract Number: 2591

Association Between Changes in Bone Quality Parameters and Inflammatory Ratios in Postmenopausal Women Treated With Romosozumab: A Retrospective Observational Study
Abstract Number: 2592

Romosozumab and Denosumab Combination Therapy in Postmenopausal Osteoporosis
Abstract Number: 2593

Single Switch from Reference Denosumab to TVB-009 in Women with Postmenopausal Osteoporosis: Analysis of the Phase 3, Randomized, Double-Blind, Multinational, Multicenter Study
Abstract Number: 2594

Comparing Immunogenicity Between TVB-009 and Reference Denosumab in Healthy Adults and Participants with Postmenopausal Osteoporosis
Abstract Number: 2595

Impact of Different Types of Physical Activity on Bone Health in Patients with Inflammatory Rheumatic Diseases: a Cross-Sectional Analysis from a Prospective Cohort Study
Abstract Number: 2596

Predicting Osteoporosis Using Routine Clinical Data: A Machine Learning Approach
Abstract Number: 2597

Altered Tryptophan Metabolism in Neuropsychiatric Lupus: A Cluster Analysis to Identify Distinct Subgroups
Abstract Number: 2598

Keratinocyte-Secreted Leukemia Inhibitory Factor Counteracts Type I IFN-Induced Antigen-Presenting Phenotype in Melanocytes: Utility in Cutaneous Lupus Skin

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].